Program
ZT002
A development code. Also written as “ZT002 Injection”, “ZT002 injection, metformin, warfarin” and “ZT002 injection, rosuvastatin, digoxin”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing QL Biopharmaceutical | 84 open or running | phase 3since Nov 13, 2025 | Apr 10, 2024 | Dec 5, 2026phase 1 · NCT07550816 |
| QL Biopharmaceutical Australia Pty | 10 open or running | phase 1since Aug 1, 2022 | Aug 1, 2022 | none ahead |
Also a collaborator on its studies: novotech-australia-pty-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 1, 2022First study: phase 1 study in Diabetes Mellitus, Type 2New to QL Biopharmaceutical Australia PtyQL Biopharmaceutical Australia Pty · NCT05491421 · 32 enrolled · Australia
- Apr 10, 2024Beijing QL Biopharmaceutical's first study: phase 1 study in OverweightNew to Beijing QL BiopharmaceuticalBeijing QL Biopharmaceutical · NCT06371326 · 28 enrolled · China
- May 16, 2024Phase 1 study in Diabetes Mellitus, Type 2Beijing QL Biopharmaceutical · NCT06423872 · 28 enrolled · China
- Jun 6, 20252 phase 2 studiesBeijing QL Biopharmaceutical · NCT07065032, NCT07020884
- Nov 13, 2025Phase 3 study in OverweightBeijing QL Biopharmaceutical · NCT07230119 · 755 enrolled · China
- Apr 20, 2026Phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07550816 · 60 enrolled · China
- Jun 29, 2026Phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07697846 · 40 enrolled · China
- Aug 31, 2026Phase 2 study in ObesityBeijing QL Biopharmaceutical · NCT07812597 · 210 planned · China
Ahead
- Dec 5, 2026Primary completion: phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07550816
- Jan 13, 2027Primary completion: phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07697846
- May 29, 2027Primary completion: phase 3 study in OverweightBeijing QL Biopharmaceutical · NCT07230119
- Jan 13, 2028Primary completion: phase 2 study in ObesityBeijing QL Biopharmaceutical · NCT07812597
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07812597Obesity · China | 2 | Not yet recruiting | Beijing QL Biopharmaceutical | Jan 13, 2028 | 210 |
| NCT07697846Overweight · China | 1 | Active, not recruiting | Beijing QL Biopharmaceutical | Jan 13, 2027 | 40 |
| NCT07550816Overweight · China | 1 | Active, not recruiting | Beijing QL Biopharmaceutical | Dec 5, 2026 | 60 |
| NCT07230119Overweight · China | 3 | Active, not recruiting | Beijing QL Biopharmaceutical | May 29, 2027 | 755 |
| NCT07065032Diabetes Mellitus, Type 2 · China | 2 | Completed | Beijing QL Biopharmaceutical | Jul 22, 2024 | 27 |
| NCT07020884Overweight · China | 2 | Completed | Beijing QL Biopharmaceutical | May 7, 2025 | 303 |
| NCT06423872Diabetes Mellitus, Type 2 · China | 1 | Completed | Beijing QL Biopharmaceutical | Oct 20, 2023 | 28 |
| NCT06371326Overweight · China | 1 | Completed | Beijing QL Biopharmaceutical | Apr 15, 2024 | 28 |
| NCT05491421Diabetes Mellitus, Type 2 · Australia | 1 | Completed | QL Biopharmaceutical Australia Pty | Apr 28, 2023 | 32 |
How it is read
Names in the registry
- “ZT002 Injection”, 4 entries
- “ZT002”, 2 entries
- “ZT002 injection, metformin, warfarin”, 1 entry
- “ZT002 injection, rosuvastatin, digoxin”, 1 entry
- “ZT002 injection”, 1 entry
Codes read as this program: ZT002.
Conditions, from the studies’ own filings
- Obesity, 6 studies
- Diabetes Mellitus, Type 2, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.